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Abstract
Background: Extracorporeal carbon dioxide removal (ECCO2R) has been gaining interest
to potentially facilitate gas transfer and equilibrate mild to moderate hypercapnic
acidosis, when standard therapy with non-invasive ventilation is deemed refractory.
However, concern regarding the effectiveness of low-flow CO2 removal remains.
Additionally, the prospect to steadily reduce hypercapnia via low-flow ECCO2R
technique is limited, especially with regional anticoagulation which potentially
reduces the risk of bleeding. Therefore, an in vivo study was conducted to determine
the efficacy of CO2 removal through a modified renal dialysis unit during the carbon
dioxide dialysis study using systemic and regional anticoagulation.
Methods: The acute study was conducted for 14 h in landrace pigs (51 ± 3 kg). CO2
removal using a diffusion membrane oxygenator substituting the hemoconcentrator
was provided for 6 h. Blood and gas (100 % O2) flows were set at 200 and 5 L/min,
respectively. Anticoagulation was achieved by systemic heparinization (n = 7) or
regional trisodium citrate 4 % (n = 7).
Results: The CO2 transfer was highest during the initial hour and ranged from 45 to
35 mL/min, achieving near eucapnic values. Regional and systemic anticoagulation
were both effective in decreasing arterial pCO2 (from 8.9 ± 1.3 kPa to 5.6 ± 0.8 kPa and
from 8.6 ± 1.0 kPa to 6.3 ± 0.7 kPa, p < 0.05 for both groups, respectively). Furthermore,
pH improved (from 7.32 ± 0.08 to 7.47 ± 0.07 and from 7.37 ± 0.04 to 7.49 ± 0.01, p < 0.05)
for both regional and systemic anticoagulation groups, respectively. Upon ceasing CO2
dialysis, hypercapnia ensued. The liver and kidney function test results were normal, and
scanning electron microscopy analysis revealed only some cellular and fibrin adhesion on
the oxygenator fibre in the heparin group.
Conclusions: CO2 dialysis utilizing either regional or systemic anticoagulation showed to
be safe and effective in steady transfer of CO2 and consequently optimizing pH.
Keywords: Acute-on-chronic hypercapnic respiratory failure, Low-flow CO2
removal, Regional anticoagulation, Systemic anticoagulation, Animal model
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Background
Chronic obstructive pulmonary disease (COPD) patients presenting with mild to mod-
erate hypercapnic respiratory acidosis are often supported by non-invasive ventilation
(NIV) to facilitate gas transfer and prevent progression into severe acidosis [1]. In
about 25 to 50 % of these patients, NIV may not be effective in improving the respira-
tory mechanics with a consequent need for invasive ventilation [2]. Hence, alternative
approaches to facilitate gas transfer have been sought, including the application of
extracorporeal carbon dioxide removal (ECCO2R) technique [3]. ECCO2R technique
primarily supports decarboxylation and thereby improves respiratory acidosis, finding
its application relevant in reversible type 2 respiratory failure situations.
CO2 is primarily transported in a dissolved state in plasma and can be extracted effect-
ively through a membrane lung when connected to high sweep gas flows [4, 5]. Other de-
terminants that influence gas transfer are membrane surface area, partial pressure of CO2
(pCO2) concentration before the membrane lung, and even the type of membrane [5–7].
Terragni et al. describe that ECCO2R application at sweep gas flows of 6 to 8 L/min and
blood flows of approximately 500 mL/min has shown to extract approximately 80 mL of
CO2/min, which accounts for 40 % of the calculated CO2 production [3]. While Burki et
al. in a pilot study reported that with ECCO2R application at low blood flow (approxi-
mately 500 mL/min), a subset of patients with underlying COPD could be managed with-
out invasive mechanical ventilation [8]. Although, these described techniques require the
use of specially designed cannula or even devices [9–11] that could increase the health-
care costs. Since COPD is a growing concern world-wide, adapting a pre-existing renal
dialysis unit and providing CO2 removal at even lower blood flows through the modified
system could potentially support patients over an extended period of time to avert rapid
correction of the acid-base balance in mild to moderate acidosis, when NIV is contra-
dicted or proves to be insufficient.
Furthermore, to prevent clotting of the extracorporeal circuit, heparin is administered
as a systemic anticoagulant [8]. However, heparin induces bleeding and has been re-
ported up to 40 % of patients placed on veno-venous extracorporeal support [12, 13].
Thus, this concern also extends to the application of ECCO2R technique. Alternatively,
regional anticoagulation likely circumvents heparin-induced bleeding and seems to be
an attractive option [14]. Regional anticoagulation with trisodium citrate has been ex-
tensively used to maintain circuit patency with safer and simple protocols in renal re-
placement therapy [15, 16]. Moreover, exogenously administered citrate metabolizes to
sodium bicarbonate [17], which might be beneficial in acute respiratory acidosis. How-
ever, this chemical buffering effect in low-flow ECCO2R systems has not been verified.
We hypothesize that implementing dialysis flows and opting for regional anticoagulation
with trisodium citrate might benefit patients with hypercapnic respiratory failure. There-
fore, in a swine model, the efficacy of CO2 removal at a dialysis flow rate using regional tri-
sodium citrate anticoagulant and also systemic anticoagulant was determined utilizing a
modified renal dialysis unit.
Methods
This in vivo study was conducted at the Department of Cardiothoracic Surgery, Experi-
mental Laboratory, Maastricht University, the Netherlands. The study was approved by
the local animal investigation committee of the Maastricht University. Animal handling
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was in accordance with the guide and use of laboratory animals (published by the Na-
tional Institute of Health, USA).
Overview of study
Fourteen healthy domestic landrace pigs weighing 51 ± 3 kg were studied. The animals
were divided into two groups based on either systemic anticoagulation with heparin
(group 1, n = 7) or regional anticoagulation using 4 % trisodium citrate (group 2, n = 7).
Each experiment was conducted over a duration of 14 h, divided into four subsequent
phases: stabilization phase (0–60 min), hypercapnic phase (60–360 min), intervention
phase (360–720 min), and post-intervention phase (720–840 min).
Animal preparation
The animals were sedated with a mixture of intramuscular administrated ketamine
(10 mg/kg), midazolam (0.5 mg/kg), and atropine (0.04 mg/kg). Induction of anaesthe-
sia and analgesia was achieved by an intravenous injection of thiopental sodium (5 mg/
kg), midazolam (0.5 mg/kg), and sufentanyl citrate (6 μg/kg). Following endotracheal
intubation, mechanical ventilation (Datex Engstrom, Instrumentarium Corporation,
Helsinki, Finland) was ensued and animals were stabilized on a volume-controlled set-
ting with a respiratory rate (RR) of 10–12 breaths/min, a tidal volume (Vt) of 10 mL/
kg/min, a positive end expiratory pressure (PEEP) of 3 cm of H2O, a fraction of in-
spired oxygen (FiO2) of 0.5, and an inspiratory is to expiratory (I:E) ratio of 1:2.
Anaesthesia, analgesia, and muscle relaxation were maintained with intravenous admin-
istration of midazolam (1.0 mg/kg/h) additionally supported by Isoflurane (0.5–1 %),
sufentanyl citrate (4 μg/kg/h), and pancronium bromide (0.1 mg/kg/h). Limb lead electro-
cardiogram (ECG) and oxygen saturation (ML320/E Oximeter POD, PowerLab, AD In-
struments, Oxfordshire, UK) were recorded and monitored continuously. Body
temperature was maintained within normal range (37.5–38.0 °C). Intravenous infusion
of Ringer’s lactate was provided. The femoral vessels (artery and vein) and pulmonary
artery were catheterized to measure the mean arterial pressure, central venous pres-
sure, and cardiac output.
Hypercapnic phase
The hypercapnic phase was induced by resetting the ventilator to a lower Vt of 6 ml/
kg/min, while maintaining other baseline parameters (RR 10–12 breaths/min, PEEP
3 cm H2O, FiO2 0.5, and an I:E ratio of 1:2). The reduced Vt of 40 % was maintained
for the remainder period of the experiment.
CO2 dialysis unit set-up and cannulation procedure
The CO2 dialysis unit consisted of a continuous veno-venous hemofiltration device (Bax-
ter BM11, Baxter Healthcare Corporation, Deerfield, IL, USA), a Bio-line coated diffusion
membrane oxygenator (0.8 m2, Quadrox-iD paediatric, Maquet Cardiopulmonary, Rastatt,
Germany) that replaced the hemoconcentrator (as shown in Fig. 1) and was primed with
200 mL of 4 % Gelofusine (B. Braun AG, Melsungen, Germany). At end of the hypercap-
nic phase, the animals in group 1 received an intravenous bolus injection of heparin
(20 IU/kg) and the right internal jugular vein was catheterized using a regular single
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double lumen dialysis catheter (14 Fr. × 10”, 25 cm; Arrow international, Reading, PA,
USA). A continuous infusion of heparin at the inflow port of the dialysis catheter main-
tained the activated partial thromboplastin time (aPTT) between 60 and 80 s, measured
hourly. In group 2, the regional anticoagulation was started as soon as the catheter was
placed through the inflow port of the dialysis catheter. In both groups, 100 mL of priming
volume was discarded immediately after the circuit was connected to the dialysis catheter.
The correct placement of the dialysis catheter was confirmed by fluoroscopy.
Intervention phase
The sweep gas flows (100 % O2) through the diffusion membrane were titrated to 5 L
of oxygen, and the blood flow was maintained at 200 mL/min. In group 2, Ringer’s lac-
tate infusion was tapered accordingly, since there was continuous infusion of 4 % triso-
dium citrate at the inflow port of the catheter, which chelated the ionized calcium of
inflowing blood. A continuous infusion of calcium gluconate 10 % at the outflow port
of the catheter maintained the systemic ionized calcium. Monitoring of anticoagulation
in this group was performed by hourly measurement of the ionized-calcium levels at
the post-oxygenator and in the animal. The infusions of 4 % trisodium citrate and cal-
cium gluconate were titrated accordingly to maintain the ionized-calcium level between
0.25 and 0.35 mmol/L [15] in the dialysis circuit and a systemic ionized-calcium level
of 1.12–1.20 mmol/L.
Post-intervention phase
The CO2 dialysis was terminated, and the dialysis circuit was disconnected after clamp-
ing the inflow and outflow ports. The animals continued to be on mechanical ventila-
tion, while the disposable parts of the circuits were separated, flushed with saline, and
visually inspected for clot formation. Parts of the diffusion membrane were collected
for scanning electron microscopy (SEM) analysis, and following post-intervention
Dialysis unit
Oxygenator
Fig. 1 In vivo extracorporeal carbon dioxide removal study unit set-up; the hemodialyzer is replaced by
diffusion membrane oxygenator (0.8 m2, Quadrox-iD paediatric), blood flow set at 200 mL/min, and
sweep gas flow at 5 L/min (100 % O2)
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phase, the animals were euthanized under general anaesthesia using a single dose of
pentobarbital (150 mg/kg).
Measurements
Hourly samples for blood gases were drawn and analysed (Gem Premier 3000, Instru-
mentation Laboratory, Lexington, MA, USA). Blood samples for liver function and
renal function tests were collected to monitor the acute metabolic effects of citrate.
The aPTT was measured using a Hemochron Jr. Signature (Edison, USA). Cardiac out-
put was measured by thermo-dilution.
CO2 transfer rate was calculated using the following formula:
CO2 transfer rate ¼ Qgas  Percentage of CO2  10
where Qgas is the gas flow through the oxygenator and percentage of CO2 is the CO2 at
the gas outlet port of the oxygenator, measured by capnograph (Novametrix Capnogard,
Philips Respironics, Best, The Netherlands).
Statistical analysis
Statistical analysis was performed with SPSS 21.0 software (SPSS, Chicago, IL, USA).
Continuous data are presented as mean ± standard deviation or median with interquar-
tile range as appropriate. The continuous variables were subjected to normality distri-
bution. Accordingly, continuous variables of paired samples within the group were
analysed by the Wilcoxon signed-rank test, and differences between two continuous
variables were analysed by the Mann-Whitney U test. A p value <0.05 was considered
statistically significant.
Results
CO2 dialysis (200 mL/min) with systemic anticoagulation (group 1) and regional antic-
oagulation (group 2) was applied in an in vivo study. The physiological parameters (e.g.
mean blood pressure, heart rate, and cardiac output) remained within normal physio-
logical limits.
CO2 transfer across the oxygenator was maximal at 45 mL/min and stabilized during
the course of the intervention at 35 mL/min in both groups (p > 0.05). Furthermore,
the mean pCO2 values/unit time during intervention were not significantly different be-
tween the groups that received systemic anticoagulation vs. regional anticoagulation
(p > 0.05). A steady CO2 removal was observed in both groups, as depicted by the mean
changes in arterial pCO2 (Fig. 2).
Consequently, pH improved from 7.32 ± 0.08 to 7.47 ± 0.07 in group 1 and from 7.37 ±
0.04 to 7.49 ± 0.01 in group 2, p < 0.05 for both groups (Table 1). Further, in group 1, a sig-
nificant change in pCO2 was observed at the first hour of intervention and at different
time points during the experimental phase. In contrast, in group 2, equilibration of CO2
reflected by changes in pCO2 occurred throughout the intervention phase (Table 2).
The arterial pO2 during intervention remained at a mean of 13.2 ± 0.3 kPa in group 1
while it was a mean of 14.1 ± 0.7 kPa in group 2. Transoxygenator pressure difference
varied between 10 and 15 mmHg. The liver function tests (alkaline phosphatase 88.0 ±
11.0 IU/L; gamma glutaryl transferase 14 ± 2.0 IU/L; aspartate aminotransferase 22.0 ±
5.0 IU/L; alanine aminotransferase 44.0 ± 2.0 IU/L; total bilirubin 2.2 ± 0.2 μmol/L;
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direct bilirubin 2.2 ± 0.2 μmol/L) and renal function test (creatinine103.0 ± 0.7 μmol/L)
were within normal range. SEM analysis (Fig. 3a) of the diffusion membrane revealed only
some cellular and fibrin adhesion on the oxygenator fibre in the heparin group (Fig. 3b).
Discussion
Low-flow CO2 removal was efficient in establishing eucapnia in a swine model. A mean
CO2 extraction of 40 mL/min through a modified renal dialysis unit permitted adequate
gas transfer under constant low volume ventilatory support. Consequently, arterial pH im-
proved within the initial hour of intervention, highlighting the efficacy of the gas-
exchange diffusion membrane even at a low blood flow rate.
Hypercapnic respiratory failure worsens prognosis and increases mortality in COPD pa-
tients [18, 19]. The pathophysiological alterations precipitating this condition include dy-
namic hyperinflation and expiratory flow limitation as a result of respiratory muscle
fatigue, which further aggravates respiratory acidosis. NIV is therefore considered as a
standard mode of treatment to provide ventilation support among these patients, to im-
prove acidemia (pH ≤7.35 and/or arterial pCO2 ≥6.0 kPa [1]. In the majority of patients,
NIV application has been found effective to avert imminent respiratory arrest. However, a
well-demarcated contradiction to apply NIV is the presence of co-morbidities [20]. More-
over, failure of NIV hinders its application or even the effectiveness of the therapy.
Table 1 Arterial pH levels between consecutive time points during CO2 dialysis
Group 1 Group 2
p value p value
End of the hypercapnic phase 7.37 ± 0.04 7.32 ± 0.08
t = 60 min 7.43 ± 0.06 0.01 7.37 ± 0.08 0.02
t = 120 min 7.44 ± 0.05 0.03 7.45 ± 0.09 0.06
t = 180 min 7.45 ± 0.05 0.03 7.45 ± 0.10 0.03
t = 240 min 7.48 ± 0.06 0.02 7.51 ± 0.10 0.02
t = 300 min 7.49 ± 0.01 0.01 7.52 ± 0.10 0.02
t = 360 min 7.49 ± 0.01 0.01 7.47 ± 0.07 0.02
pH values are expressed as mean ± SD; group 1: heparin group; group 2: citrate group; t: sampling time point; p values






















Changes in arterial pCO2 throughout the study
group 1
group 2
Fig. 2 Changes in arterial pCO2 during CO2 dialysis. Values are expressed as mean±SD; Stabilisation (0-60 min);
Hypercapnic phase (60-360 min); Intervention phase (360-720 min); Post-intervention phase (720-840 min);
group1: heparin group; group 2: citrate group
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Table 2 Arterial pCO2 levels between consecutive time points during CO2 dialysis
Group 1 Group 2
p value p value
End of the hypercapnic phase 8.9 ± 1.3 8.6 ± 1.0
t = 60 min 7.8 ± 1.2 0.01 7.8 ± 1.3 0.02
t = 120 min 7.3 ± 0.9 0.11 7.2 ± 1.1 0.04
t = 180 min 7.2 ± 0.9 0.13 6.8 ± 1.0 0.02
t = 240 min 6.8 ± 0.9 0.01 6.2 ± 0.8 0.02
t = 300 min 6.4 ± 0.6 0.01 5.9 ± 0.7 0.02
t = 360 min 6.3 ± 0.8 0.91 5.6 ± 0.8 0.03
pCO2 values are expressed as mean ± SD; group 1: heparin group; group 2: citrate group; t: sampling time point; p values
are expressed for two consecutive sample points within a group during CO2 dialysis
Fig. 3 a Scanning electron micrograph of an oxygenator fibre in the heparin group showing some cellular
and fibrin adhesion. b Scanning electron micrograph of an oxygenator fibre in the citrate group
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Consequently, an invasive approach to provide ventilation is applied, which is associated
with a poor survival rate [21]. Therefore, a minimally invasive form of support through
extracorporeal CO2 removal technology has been increasingly considered as a viable alter-
native to standard therapies [3].
In the recent years, application of ECCO2R devices has been gathering interest to
support patients in hypercapnic respiratory failure refractory to standard therapy [3, 8].
As application of ECCO2R has been demonstrated to be effective, using blood flows of
about 400–1000 mL/min supports gas transfer and ameliorates moderate to severe hy-
percapnic acidosis [8, 22], thereby reducing pCO2 (from 10.5 to 8.7 kPa) and improving
pH (from 7.28 ± 0.08 to 7.34 ± 0.07) following 1 h of support at a blood flow rate of ap-
proximately 500 mL/min [8]. Recently, Kargiannidis et al. reported a swine study which
showed improvement of pCO2 (from about 14.4 to 7.5 kPa) with acidemia equilibrating
from 7.13 ± 0.08 to 7.41 ± 0.07 within 15 min of ECCO2R support at a blood flow rate
of 1000 mL/min [22]. Albeit, one of the largely unrecognized concern prevails among
such patients when hypercapnia is optimized too rapidly, resulting in metabolic alkal-
osis which can increase the duration of recovery and hospital stay [23]. Moreover, in
situations of acute-on-chronic hypercapnic respiratory failure, a steady removal of CO2
might be necessary for an extensive period of time, as CO2 persists in HCO3-form in
slow compartments [22]. Extensive periods of high-flow ECCO2R support might prove
counter-productive, as we might plausibly alter the acid-base balance dramatically.
Therefore, low-flow CO2 removal would be a more controlled and physiological alter-
ation to establish homeostasis in a chronically altered state. As described in our study,
a commonly used renal dialysis unit was adapted by incorporating a diffusion mem-
brane oxygenator replacing the hemodialyzer. CO2 dialysis in our observation resulted
in a lower CO2 extraction (approximately 40 mL/min) compared to currently available
veno-venous pump-driven devices (approximately 80 mL/min) [9, 11]. Although, CO2
dialysis in this current study seems to have a lower CO2 extraction rate, the ability to
increase blood flows with prevalent dialysis devices provides the possibility to increase
higher amount of CO2 extraction when indicated, while opting for a larger size cannula.
In patients with underlying renal insufficiency and acute respiratory distress syndrome,
Forster and colleagues described the role of low-flow CO2 removal, where the introduc-
tion of a hollow-fibre oxygenator in a renal replacement unit ameliorated acidosis and
improved pCO2 [24]. Although this auxiliary support facilitated improvements, the risk
of anticoagulation failure leading to clot formation or bleeding with systemic anticoagu-
lation remains a challenge.
In general, an extracorporeal device such as CO2 removal system requires systemic
anticoagulation [25], to maintain patency and reduce thromboembolic complications. To
date, heparin remains the most commonly used anticoagulant in these devices, potentially
increasing the risk of bleeding. Additionally, the use of unfractionated heparin in patients
susceptible for bleeding can induce thrombocytopenia and hence propagate the risk of
systemic bleeding [12, 26]. It would be, therefore, attractive to implement regional antic-
oagulation with citrate as practised widely in renal dialysis [15] to reduce the potential risk
of bleeding. The practice of regional anticoagulation in CO2 removal has not been preva-
lent. Cardenas et al. described the use of regional citrate anticoagulation in a CO2 removal
system, but they were challenged with the maintenance of adequate systemic calcium
levels [27]. In our study, we used a standard protocol for regional citrate anticoagulation,
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where citrate was infused into the inlet port of the catheter chelating calcium. The che-
lated calcium inhibited the activation of calcium-dependent coagulation factors in the dia-
lysis circuit, providing optimum anticoagulation. The infusion of calcium gluconate in the
outlet port of the catheter reversed the citrate effect.
The use of regional anticoagulation with citrate also has additional benefits, such as
improving the circuit survival time [15]. Moreover, the secondary gain in administering
trisodium citrate is the formation of sodium bicarbonate, which is an end-product of
citrate metabolism occurring in the liver, skeletal muscle, and kidney [17]; this might
buffer the excess acid. However, this beneficial chemical buffering of CO2 was observed
less evidently, conceivably in view of the efficient CO2 dialysis system.
Gross thrombus formation, a potential complication in low-flow conditions, was not ob-
served in either the heparin group or the citrate group. Although SEM analysis from the
heparin group revealed only some cellular and fibrin adhesion over the diffusion mem-
brane, similar observations were not prominent from the analysis in the citrate group.
This latter observation might be due to the chelation of calcium and subsequent decrease
in the inflammatory reactions that reduce the activation of leukocytes and monocytes
[28], leading to less adhesion.
We recognized some limitations with this study. First, the use of healthy animals did
not allow us to completely mimic the acute-on-chronic hypercapnic respiratory failure,
where severe airflow limitation could not be simulated. Additionally, this limitation also
prevents us to understand what could potentially challenge in clinical practice if there
were to be device failure in non-ventilated patients. Furthermore, increasing acidosis
(pH <7.25) over an extended period could not be replicated, due to a potential source
of arrhythmia and, to an extent, stabilization of hypercapnic levels during the hypercap-
nic phase of the study. Nevertheless, the steady and gradual improvement in arterial
pCO2 and pH utilizing CO2 dialysis in the given circumstance proved effective in
ameliorating acute hypercapnia irrespective of the nature of anticoagulation. In the
event of prolonged support, the influence of regional anticoagulation on CO2 dialysis
circuit life is worth investigating.
Conclusions
In conclusion, we demonstrated that low-flow CO2 dialysis using a modified renal re-
placement system improved arterial pCO2 significantly, thereby optimizing pH. Fur-
thermore, regional anticoagulation with citrate would be an alternative option to
circumvent bleeding complications. However, further studies are needed to determine
if this approach is a viable option to potentially support patients with acute-on-chronic
respiratory failure.
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